

Huons Global

3Q 2023 Business Performance

2023. 11. 14.



Disclaimer

All information in this book including business performance and financial report is written by Korean-International Financial Reporting Standards(K-IFRS).

This book includes a "forecast" about future. It is not about the past, but the future business plan including expected management status and financial performance, and sometimes there can be word such as 'anticipation', 'forecast', 'plan', 'expectation', and '(E)'.

A "forecast" can mean uncertain factors which can affect the company either positively or vice versa, and those can include:


- Domestic or international financial market trends including fluctuation of foreign exchange rate or interest rate.
- · Company's very important strategic decision such as M&A
- · Unexpected business environment change in the main industry
- Other internal and external change that can affect the company's management and finance.

Because of those uncertain risks, company's actual business performance can be different from the "forecast" in this booklet. Also the information we provide is written as of the day we deliver the presentation, so it can be changed due to unexpected external status of industry or internal company's revision of strategies without any prior notice in the future.

Contents

- 1. Business Performance
- 2. Subsidiaries
- 3. A new business
- 4. Appendix

Revenue generation based on the stable performance of subsidiaries




Huons Global 2. Subsidiaries_Profit&Loss Analysis

(Unit: Million KRW)

Classification	Sales				Operating Profit				Net Profit						
	3Q23	3Q22	2Q23	YoY	QoQ	3Q23	3Q22	2Q23	YoY	QoQ	3Q23	3Q22	2Q23	YoY	QoQ
Huons Global (Consolidated)	190,617	167,565	193,744	+13.8%	-1.6%	31,901	18,230	36,549	+75.0%	-12.7%	23,387	15,730	22,802	+48.7%	+2.6%
Huons Global (Separated)	10,532	7,167	8,067	+46.9%	+30.5%	4,267	1,855	1,726	+130.0%	+147.1%	3,881	-195	-22	Turn to profit	Turn to profit
Huons	138,166	123,129	140,697	+12.2%	-1.8%	14,952	2,025	17,876	+638.4%	-16.4%	11,780	2,629	14,863	+348.1%	-20.7%
Humedix	39,655	31,891	39,763	+24.3%	-0.3%	11,355	7,847	11,393	+44.7%	-0.3%	7,215	6,207	3,280	+16.3%	+120.0%
HuM&C	12,563	10,280	12,629	+22.2%	-0.5%	1,543	361	1,432	+327.0%	+7.8%	1,143	-62	2,670	Turn to profit	-57.2%
Huons Meditech	13,643	14,453	15,096	-5.6%	-9.6%	601	2,345	1,429	-74.4%	-58.0%	204	1,867	1,817	-89.1%	-88.8%
Huons Biopharma	9,219	6,754	12,699	+36.5%	-27.4%	2,547	1,549	4,437	+64.4%	-42.6%	2,801	1,600	4,880	+75.1%	-42.6%
Huons Lab	-	-	-	-	-	-1,887	-400	-757	-	-	-1,932	-444	-806	-	-
Huons USA	282	-	201	-	+40.8%	12	-4,390	-14	Turn to profit	-	2	-3,647	-1,846	Turn to profit	-
Huons JAPAN	99	-	112	-	-12.1%	6	-147	3	Turn to profit	+78.5%	6	-146	3	Turn to profit	+77.6%

tuons Global 3. A new business





Huons Global 4. Appendix_Financial Statements

Consolidated Statement of Financial Position

[Unit: million KRW]

				-	-
Classification	3Q22	4Q22	1Q23	2Q23	3Q23
Assets	1,297,056	1,243,109	1,223,154	1,242,941	1,272,494
Current assets	602,121	611,226	585,663	586,850	605,141
Cash etc.*	362,028	364,473	323,646	306,963	318,183
Accounts receivable	104,564	107,142	114,355	124,504	124,383
Non-current assets	694,935	631,883	637,491	656,091	667,353
Liabilities	438,647	457,234	418,098	393,660	393,601
Current liabilities	332,458	367,562	333,087	306,249	303,752
Short-term borrowings	117,904	107,461	107,699	100,990	100,404
Current portion of long-term debt	-	-	6,033	6,033	21,033
Non-current liabilities	106,188	89,671	85,011	87,411	89,849
Long-term borrowings	52,826	70,826	65,000	65,000	65,000
Equity	858,410	785,876	805,056	849,281	878,894
Equity attributable to owners of parent	538,027	464,316	466,792	478,746	489,499
Retained earnings	191,113	116,845	117,427	125,298	133,299
Non-controlling interests	320,383	321,559	338,264	370,534	389,395
Stability Indicator					
Current ratio	181.1%	166.3%	175.8%	191.6%	199.2%
Debt to equity ratio	51.1%	58.2%	51.9%	46.4%	44.8%
Borrowing ratio	19.9%	22.7%	22.2%	20.3%	21.2%
Interest coverage ratio	500%	697%	665%	1,259%	1,126%

^{*} Cash etc. = Cash & Cash Equivalent + Short-term Financial Instruments

Financial Statements of Comprehensive Income

[Unit: million KRW]

Classification	3Q22	4Q22	1Q23	2Q23	3Q23
Sales	167,565	173,097	173,964	193,744	190,617
SG&A expenses	149,336	146,142	149,503	157,196	158,715
Operating Profit	18,230	26,955	24,460	36,549	31,901
Gains on valuation using equity method	295	(420)	306	(166)	152
Other revenues	5,642	(739)	2,257	3,801	1,670
Other expense	965	80,356	2,258	1,463	916
Interest expense	3,648	3,870	3,678	2,903	2,833
Profit before tax	19,603	(55,630)	33,357	31,101	32,671
Income tax expense	4,474	15,760	10,597	8,299	9,284
Net Profit	15,730	(72,189)	22,760	22,802	23,387
Profit, attributable to owners	5,963	(74,266)	6,706	7,871	11,063
Profit, attributable to non-controlling interests	9,767	2,077	16,054	14,932	12,324
A Profitability Indicator					
Operating profit ratio	10.9%	15.6%	14.1%	18.9%	16.7%
EBITDA Margin	16.5%	20.6%	19.0%	23.3%	21.5%
Net profit ratio	9.4%	-41.7%	13.1%	11.8%	12.3%
ROE**	52%	53%	54%	56%	57%
Sales/Asset**	151%	158%	152%	146%	145%

^{**} Figures accumulated for 4 quarters

Thank you